Nuwellis Inc
$ 0.15
0.14%
09 Jun - close price
- Market Cap 491,910 USD
- Current Price $ 0.15
- High / Low $ 0.15 / 0.14
- Stock P/E N/A
- Book Value 1.09
- EPS -26.89
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.10 %
- ROE -5.84 %
- 52 Week High 24.78
- 52 Week Low 0.13
About
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Analyst Target Price
$11.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-10 | 2025-11-12 | 2025-08-14 | 2025-05-13 | 2025-03-11 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 |
| Reported EPS | None | -1.5 | 0.56 | -60.99 | -28.98 | -0.44 | 73.08 | -791.7 | -0.6 | -3292.81 | -2660.71 | -5365.51 |
| Estimated EPS | -1 | -1.56 | -17.22 | -18.9 | -18.9 | -0.43 | -53.76 | -346.29 | -1.06 | -2043.3 | -4576.61 | -5914.31 |
| Surprise | 0 | 0.06 | 17.78 | -42.09 | -10.08 | -0.01 | 126.84 | -445.41 | 0.46 | -1249.51 | 1915.9 | 548.8 |
| Surprise Percentage | None% | 3.8462% | 103.252% | -222.6984% | -53.3333% | -2.3256% | 235.9375% | -128.6234% | 43.3962% | -61.1516% | 41.8629% | 9.2792% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.68 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NUWE
2026-06-09 04:10:08
Nuwellis, a medical technology company specializing in cardiorenal conditions, has successfully closed a public offering, raising approximately $6 million. This funding, obtained through common stock, pre-funded warrants, and Series C and D warrants, is intended to support the company's growth and product development efforts. The proceeds will advance Nuwellis's technologies aimed at improving patient care for both acute and chronic cardiorenal conditions.
2026-06-09 02:10:25
Nuwellis Inc. has announced the closing of a public offering, raising approximately $6.0 million in gross proceeds. The offering included the sale of common stock and pre-funded warrants, with accompanying Series C and Series D Warrants. This capital raise comes as the company's stock has decreased by 75% in the past week, and it continues to burn through cash with negative free cash flow.
2026-06-09 02:10:08
Nuwellis Inc. (NASDAQ:NUWE) has completed a public offering, raising approximately $6.0 million in gross proceeds. The offering included the sale of common stock and pre-funded warrants, along with Series C and Series D Warrants, with exercise prices set at $0.30. This capital raise occurs as the stock trades at $0.14, having dropped 75% in the past week, and the company plans further regulatory developments for its Aquadex SmartFlow System.
2026-06-09 02:10:08
Nuwellis (Nasdaq: NUWE) announced the closing of a registered public offering that generated approximately $6.0 million in gross proceeds. The offering includes common shares, pre-funded warrants, and accompanying Series C and Series D warrants, with common shares plus warrants priced at $0.30 and pre-funded warrants plus warrants at $0.2999. This financing action aligns with Nuwellis's historical pattern of using equity and warrant structures to raise capital, which has often resulted in negative stock performance post-announcement.
2026-06-09 01:50:00
Nuwellis, Inc. has successfully completed a public offering, raising approximately $6.0 million through the sale of common stock, pre-funded warrants, and accompanying Series C and D warrants. The offering involved common stock priced at $0.30 per share and pre-funded warrants at $0.2999, with Ladenburg Thalmann & Co. Inc. acting as the book-running manager. The company, which specializes in cardiorenal solutions, highlights the importance of this capital for future development despite potential concerns regarding the low share price and reliance on warrants.
2026-06-08 13:40:42
Nuwellis (NASDAQ: NUWE) is conducting a primary offering of up to 1.9 million shares of common stock, along with pre-funded warrants for up to 18.1 million shares and common warrants for up to 80 million shares. The public offering price is $0.30 per share and accompanying common warrants, with estimated net proceeds of $5.2 million if all securities are sold. The exercisability of common warrants is conditional upon stockholder approval and a reverse stock split, and there is no established trading market for the warrants.
